## Diagnosis and Investigation Strategy **Key Point:** In a patient with suspected atrial fibrillation (AF), transthoracic echocardiography is the investigation of choice to: - Confirm the diagnosis and assess cardiac structure - Evaluate left ventricular function (ejection fraction) - Assess left atrial size - Detect structural abnormalities (valvular disease, cardiomyopathy) - Guide antiarrhythmic drug selection and rate control strategy ### Why Transthoracic Echo is Preferred Echocardiography provides critical structural and functional information that directly influences management decisions: | Parameter | Clinical Significance | |-----------|----------------------| | LV ejection fraction | Determines if rate vs. rhythm control; guides drug choice (avoid Class IC in reduced EF) | | Left atrial size | Predicts AF recurrence; indicates chronicity | | Valvular pathology | Indicates need for anticoagulation; influences antiarrhythmic selection | | Wall motion abnormality | Suggests ischemic etiology; affects prognosis | **High-Yield:** The 2019 AHA/ACC/HRS Focused Update recommends transthoracic echocardiography as the initial imaging modality in all patients with newly diagnosed AF to assess structural heart disease and guide therapy [cite:Harrison 21e Ch 226]. **Clinical Pearl:** Patients with reduced ejection fraction (HFrEF) should avoid Class IC antiarrhythmics (flecainide, propafenone) and benefit from beta-blockers or amiodarone. Echocardiography identifies this critical distinction. ### Role of Other Investigations - **Holter monitor:** Used for symptom correlation and rate assessment in known AF, not for initial diagnosis confirmation - **TEE with cardioversion:** Performed only when rhythm control is planned and anticoagulation status is uncertain; not a diagnostic test - **Chest X-ray:** Non-specific; may show cardiomegaly but does not guide antiarrhythmic selection
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.